AngioDynamics

ANGO

Medical - Instruments & Supplies · Healthcare

Price

$15.75

-0.07 (-0.44%)

Market Cap

$651.0M

Exchange

NASDAQ

Winston Score

Winston is worried

Below-average fundamentals — multiple weak pillars.

Data as of Aug 23, 2026 · filings through May 31, 2026

How the score breaks down

Quality

Mixed

Growth

Mixed

Cash Flow

Weak

Stability

Data not available

Valuation

Data not available

Track this stock — start free trial

Share count rising — dilution

+6.5% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 39.0M (2022) → 41.5M (2026)

Winston Score History

The full picture

AngioDynamics makes medical devices used by doctors to treat cancer and vascular diseases. Its products include tools for removing blood clots, draining fluids, and destroying tumors using heat or electrical energy. The company sells mainly to hospitals and outpatient clinics across the United States.

AngioDynamics earns revenue by selling its devices directly to healthcare facilities, with no major subscription component. It operates primarily in the U.S. but has some international sales, and it competes against larger medical device companies like Becton Dickinson and Medtronic. The company is currently unprofitable, with negative operating and returns on capital, and its key challenge is growing its newer tumor-destruction technology fast enough to offset declining sales in its older vascular product lines.

Politician Trades

1 trades / 12mo

0 Congressional buys and 1 sell on ANGO in the last 12 months.

Unlock the full Smart Money Map — every trade plotted on the price chart with politicians, amounts and returns since each trade. Founder's Deal is $57/mo locked for life.

Unlock politician trades

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+8.0% YoY

YoY Growth Rate

Slow revenue growth

EPS Growth

-86.7% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$29M/ year

↑ Rising (+12% vs prior year)

9.2% of revenue

Below sector average (18%)

R&D investment increasing — building for the future

Insider Activity

11.6%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Position

Cash flow positive

$54M cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Company generates more cash than it spends — no dilution risk from fundraising

Growth context

AngioDynamics is growing revenue at 8% year-over-year. The Winston Score measures business quality today — these growth metrics show what could matter tomorrow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

57.1%

Premium pricing power — 57.1% gross margin

Profit after running costs

Operating Margin

-23.5%

Losing money on operations — -23.5%

Return on the money invested

ROCE

-23.4%

Weak — -23.4% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

+9.5%

Steady sales growth (+9.5% YoY)

Profit growth

EPS YoY

N/A

Data not available

How steady the profit is

EPS Consistency

5/8 quarters

Mixed — about half the quarters showed growth

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

—

Data not available

Spare cash per sale

FCF Margin

0.2%

Thin free cash flow (0.2%)

FCF margin between 0% and 10%. Some cash from sales, but not a lot.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

N/A

Data not available

Covers its interest

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial